Upcoming Earnings, Financial Results, New Affiliations, and Study Results - Research Reports on Regeneron, Valeant, CVS Health, CIGNA and Baxter

Editor Note: For more information about this release, please scroll to bottom.

NEW YORK, November 3, 2014 /PRNewswire/ --

Today, Analysts Review released its research reports regarding Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Valeant Pharmaceuticals Intl Inc. (NYSE: VRX), CVS Health Corp. (NYSE: CVS), CIGNA Corporation (NYSE: CI) and Baxter International Inc. (NYSE: BAX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7653-100free.

--
Regeneron Pharmaceuticals Inc. Research Reports
Regeneron Pharmaceuticals Inc. (Regeneron) posted on the Events and Presentations section of its official website that the Company will hold its Q3 2014 earnings conference call on November 4, 2014 at 8:30 a.m. ET. Analysts at Bloomberg Businessweek expect the Company to report Q3 2014 EPS (pre-exceptional) of $2.58 on revenue of $730 million. The full research reports on Regeneron are available to download free of charge at:

http://www.analystsreview.com/Nov-03-2014/REGN/report.pdf

--
Valeant Pharmaceuticals Intl Inc. Research Reports
On October 20, 2014, Valeant Pharmaceuticals Intl Inc. (Valeant) reported a 33.4% YoY rise in its Q3 2014 total revenues to $2.1 billion. During the quarter, the Company's product sales, which constituted 98.4% of the total revenue, improved 34.3% YoY to $2.0 billion, reflecting growth in both developed and emerging market revenues. The Company's Q3 2014 net income attributable to Valeant came in at $275.4 million or $0.81 per diluted share, compared to net loss of $973.2 million or $2.92 diluted loss per share in Q3 2013. The Company Q3 2014 diluted cash EPS stood at $2.11, above the Thomson Reuters' average analyst estimate of $1.99 per share. The Company's 9M 2014 total revenues improved 61.5% YoY to c.$6 billion, while net income attributable to Valeant came in at $378.6 million, compared to a net loss of $989.9 million in 9M 2013. For Q4 2014, the Company expects cash EPS in the range of $2.45 - $2.55, while for full-year 2014, the cash EPS is expected between $8.22 and $8.32. The full research reports on Valeant are available to download free of charge at:

http://www.analystsreview.com/Nov-03-2014/VRX/report.pdf

--
CVS Health Corp. Research Reports
On October 30, 2014, CVS Health Corp. (CVS Health) announced that it has entered into new clinical affiliations with three leading regional health systems: Baptist Health System in Alabama; Community Health Systems (CHS) affiliated hospitals which include Commonwealth Health in Pennsylvania, Northwest Medical Center, including Oro Valley Hospital in Arizona, and Tennova Healthcare in Tennessee; and Premier Health in Ohio. The Company informed that through these new affiliations, patients will gain access to high-quality and affordable health care services. Under these affiliations, patients served by these health systems will continue to have access to clinical support, medication counseling, chronic disease monitoring and wellness programs at CVS/pharmacy stores and MinuteClinic, the retail medical clinic of CVS Health. In addition, the Company will provide critical prescription and visit information to the participating health systems through the integration of secured electronic medical record (EMR) systems. The full research reports on CVS Health are available to download free of charge at:

http://www.analystsreview.com/Nov-03-2014/CVS/report.pdf

--
CIGNA Corporation Research Reports
On October 30, 2014, CIGNA Corporation (CIGNA) released its Q3 2014 and 9M 2014 earnings. The Company reported Q3 2014 total revenues of $8.8 billion, up 9% YoY, reflecting growth in premiums and fees of 7% in Global Health Care, 17% in Global Supplemental Benefits and 7% in Group Disability and Life, primarily driven by continued growth in Cigna's targeted customer segments. The Company's Q3 2014 net income stood at $534 million, compared to $553 million in Q3 2013. The Company's 9M 2014 total revenues improved 7% YoY to c.$26 billion, while net income improved 47% YoY to $1.6 billion. For full-year 2014, the Company expects consolidated adjusted income from operations in the range of $1.95 billion to $2.00 billion. The full research reports on CIGNA are available to download free of charge at:

http://www.analystsreview.com/Nov-03-2014/CI/report.pdf

--
Baxter International Inc. Research Reports
On October 30, 2014, Baxter International Inc. (Baxter) reported that it presented the results of a Phase 2/3 study of its investigational 20% concentration subcutaneous immunoglobulin treatment for primary immunodeficiencies (PI) during the biennial congress of the European Society for Immunodeficiencies, held in Prague. The Company informed that the Phase 2/3 study evaluated the efficacy, safety, tolerability and pharmacokinetics (PK) of IGSC 20% in European patients at least two years old with PI. Baxter stated that the study met its primary endpoint that measured the rate of validated acute serious bacterial infections, or VASBIs. John Orloff, MD, Vice President and Global Head of research and development for Baxter BioScience said, "Once the global studies have been completed, this data set will form the basis for regulatory submissions in the U.S. and Europe as we hope this will offer a new therapeutic alternative for patients with immune deficiency disorders around the world." The full research reports on Baxter are available to download free of charge at:

http://www.analystsreview.com/Nov-03-2014/BAX/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


SOURCE Analysts Review

Suggested Articles

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.

A group of senators is asking the FTC to take a careful look at pharma mergers given the cost of drugs in the U.S.

Life’s been tough for J&J's prostate cancer med Erleada in its battle with Pfizer-Astellas’ Xtandi. A new FDA nod could help level the playing field.…